Market closed
Relay Therapeutics/$RLAY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
294
Website
RLAY Metrics
BasicAdvanced
$788M
Market cap
-
P/E ratio
-$2.61
EPS
1.67
Beta
-
Dividend rate
Price and volume
Market cap
$788M
Beta
1.67
52-week high
$12.14
52-week low
$4.25
Average daily volume
2.2M
Financial strength
Current ratio
18.42
Quick ratio
17.876
Long term debt to equity
5.279
Total debt to equity
5.938
Management effectiveness
Return on assets (TTM)
-26.87%
Return on equity (TTM)
-42.69%
Valuation
Price to revenue (TTM)
62.221
Price to book
0.94
Price to tangible book (TTM)
0.94
Price to free cash flow (TTM)
-2.203
Growth
Revenue change (TTM)
-61.22%
Earnings per share change (TTM)
-2.54%
3-year revenue growth (CAGR)
-51.01%
3-year earnings per share growth (CAGR)
-2.74%
What the Analysts think about RLAY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
RLAY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RLAY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RLAY News
AllArticlesVideos
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
GlobeNewsWire·3 days ago
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
GlobeNewsWire·5 days ago
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $788M as of December 14, 2024.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of December 14, 2024.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.